In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Boehringer Ingelheim, GPC Biotech to discover therapy for HPV

13 Feb 2001

Executive Summary

GPC Biotech (genomics, proteomics) will use its OliCode, PathCode, and bioinformatics technologies to identify targets and molecular pathways associated with high- and low-risk infections for Boehringer Ingelheim to develop and market drugs to prevent and treat human papillomavirus (HPV) infections.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By